Piper Sandler Maintains Overweight on Monopar Therapeutics, Raises Price Target to $95
Benzinga Newsdesk 1 year ago
NewsPrice TargetSmall CapAnalyst Ratings
Piper Sandler analyst Biren Amin maintains Monopar Therapeutics (NASDAQ: MNPR) with a Overweight and raises the price target from $76 to $95.
Piper Sandler analyst Biren Amin maintains Monopar Therapeutics (NASDAQ: MNPR) with a Overweight and raises the price target from $76 to $95.